Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why

Enlivex Therapeutics (ENLV) is a clinical-stage pharmaceutical company focused on developing its lead pipeline candidate, Allocetra, an off-the-shelf cell therapy.Enlivex designed Allocetra to reprogram macrophages into their homeostatic state. The therapy is being evaluated in a mid-stage study for treating organ failure associated with sepsis.In the past week, the company’s stock lost 51.2%. This downside came after management came out with mixed results from the phase II study evaluating Allocetra over 2 ...